01—Abstract
Summary
Summary of the 8-K filed February 12, 2024. Cited figures are marked; the original filing is the authoritative source.
On February 11, 2024, Gilead Sciences (GILD) entered into a definitive Merger Agreement to acquire CymaBay Therapeutics (CBAY) for $32.50a per share in cash, implying a total equity value of about $4.3 billion and a 27% premium to CymaBay's February 9, 2024 closing price.
The deal is structured as a two-step transaction: a Gilead subsidiary (Pacific Merger Sub, Inc.) will launch a tender offer, followed by a second-step merger under DGCL Section 251(h) at the same price for any shares not tendered. Completion requires a majority tender, expiration or termination of the HSR waiting period, and no prohibiting law or order. The companies expect closing in the first quarter of 2024.
The strategic rationale centers on seladelpar, CymaBay's lead investigational oral PPARδ agonist for primary biliary cholangitis (PBC), including pruritus. The FDA has accepted the New Drug Application with priority review and a PDUFA target date of August 14, 2024, and seladelpar holds Breakthrough Therapy, PRIME, and Orphan designations. Phase 3 RESPONSE trial data showed biochemical response of 61.7%b versus 20.0% for placebo.
Gilead expects the deal to be approximately neutral to EPS in 2025 and significantly accretive thereafter, and it expects the acquisition to enhance revenue growth once seladelpar is approved. For investors, the key items are the modest size of the deal relative to Gilead's scale, the single-asset pipeline risk concentrated in seladelpar, and the deal protections: a no-shop clause with a fiduciary out for superior proposals, and a $151.6 millionc termination fee payable by CymaBay in certain circumstances. The filing also includes extensive cautionary language, and the representations and warranties are qualified by confidential disclosure schedules, so the filing alone does not establish the factual condition of either company.
02—Key points
Key Highlights
- Gilead will acquire CymaBay Therapeutics for $32.50 per share in cash, a total equity value of about $4.3 billion, representing a 27% premium to CymaBay's February 9, 2024 closing price.
- The transaction is a two-step structure: a tender offer by Pacific Merger Sub, Inc. (a Gilead subsidiary), followed by a Section 251(h) DGCL merger for remaining shares at the same price.
- Tender offer conditions include a majority of outstanding shares tendered (on a basis that counts Gilead's existing holdings), HSR Act waiting period expiration, and no prohibiting law or order.
- The core asset is seladelpar, an oral PPARδ agonist for PBC; the NDA has FDA priority review with a PDUFA target date of August 14, 2024, and U.S. approval is anticipated in Q3 2024.
- Phase 3 RESPONSE data showed biochemical response of 61.7% for seladelpar versus 20.0% for placebo, and normalization of alkaline phosphatase at 12 months of 25.0% versus 0.0%.
- Gilead expects the deal to be approximately EPS-neutral in 2025 and significantly accretive thereafter; closing is anticipated in Q1 2024.
- A $151.6 million termination fee is payable by CymaBay to Gilead in specified circumstances, including termination to accept a Superior Offer, and the merger agreement includes customary no-shop restrictions.
03—Questions
Frequently Asked Questions
How much is Gilead paying for CymaBay, and what is the premium?
Gilead is paying $32.50 per share in cash, a total equity value of about $4.3 billion. The price represents a 27% premium to CymaBay's closing share price on February 9, 2024, the last trading day before the announcement.
What is the deal structure and when is it expected to close?
The deal begins with a tender offer by a wholly owned Gilead subsidiary for all outstanding CymaBay shares, which must be open for at least 20 business days. Any shares not tendered are acquired in a second-step merger under DGCL Section 251(h) at the same price. Closing is expected in the first quarter of 2024, subject to HSR clearance and other customary conditions.
Why is Gilead acquiring CymaBay, and what is the key asset?
The key asset is seladelpar, an investigational oral PPARδ agonist for primary biliary cholangitis (PBC), a rare chronic liver disease. Gilead says it will leverage its liver disease expertise to advance seladelpar. It has FDA priority review and a PDUFA date of August 14, 2024, and the deal is expected to enhance revenue growth after approval.
What are the main risks to completing the transaction?
Risks include uncertainty about how many CymaBay shareholders will tender, the possibility of competing offers, failure to satisfy or waive closing conditions (including a governmental prohibition or delay), and the difficulty of predicting regulatory timing. Clinical, regulatory, and integration risks for seladelpar are also cited in the forward-looking statements.
What protections does the merger agreement provide, and what happens if the deal fails?
The agreement includes no-shop restrictions on CymaBay, though the board may engage with an unsolicited bona fide proposal that it determines is or could reasonably lead to a Superior Offer if its fiduciary duties require. CymaBay would pay Gilead a $151.6 million termination fee in specified circumstances, including termination to accept a Superior Offer.
04—Continue